Insider Selling: Liquidia (NASDAQ:LQDA) CFO Sells $37,533.54 in Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 1,166 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.19, for a total value of $37,533.54. Following the completion of the sale, the chief financial officer directly owned 353,823 shares of the company’s stock, valued at approximately $11,389,562.37. This trade represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, October 13th, Michael Kaseta sold 11,630 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total transaction of $272,258.30.

Liquidia Price Performance

LQDA opened at $33.92 on Friday. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -23.56 and a beta of 0.48. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 1 year low of $10.37 and a 1 year high of $34.08. The stock has a fifty day moving average price of $26.04 and a 200 day moving average price of $21.73.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. The company’s quarterly revenue was up 1106.7% compared to the same quarter last year. Analysts forecast that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC grew its holdings in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares in the last quarter. Vanguard Group Inc. boosted its position in Liquidia by 10.2% during the third quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock valued at $90,078,000 after purchasing an additional 367,659 shares during the last quarter. Opaleye Management Inc. grew its stake in Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares in the last quarter. TCG Crossover Management LLC acquired a new position in shares of Liquidia during the 3rd quarter worth approximately $38,887,000. Finally, Caprock Group LLC bought a new stake in shares of Liquidia during the 3rd quarter worth approximately $37,114,000. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LQDA. Wells Fargo & Company initiated coverage on Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 target price for the company. HC Wainwright upped their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. BTIG Research reissued a “buy” rating and issued a $49.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a report on Tuesday, November 4th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price target on shares of Liquidia in a research report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).